REFERENCES
http://www.fda.gov/cder/ogd/rld/50733s4.PDF.
Principi N, Esposito S: Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Safety 20:25–41, 1999
Kuzman I, Soldo I, Schonwald S, Culig J: Azithromycin for treatment of community acquired pneumonia caused by legionella pneumophilia: a retrospective study. Scand J Infect Dis 27:503–505, 1995
Gholson C, Warren G: Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med. 150:215–216, 1990
Longo G, Valenti C, Gandini G, Ferrara L, Bertesi M, Emilia G: Azithromycin-induced intrahepatic cholestasis. Am J Med 102:217–218, 1997
Casaval, RI, Lanchaster, DJ: Hypersensitivity syndrome associated with azithromycin. Am J Med 110:330–331, 2001
George DK, Crawford D: Antibacterial-induced hepatotoxicity: incidence, prevention, management. Drug Safety 15:79–85, 1996
Braun P: Hepatotoxicity of erythromycin. J Infect Dis 119:300–306, 1969
Derby LE, Jick H, Henry DA, Dean AD: Erythromycinassociated cholestatic hepatitis. Med J Aust 158:600–602, 1993
Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA: Pharmacokinetic and in vivo studies with azithromycin (CP-62, 993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 31:1948–1954, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chandrupatla, S., Demetris, A.J. & Rabinovitz, M. CASE REPORT: Azithromycin-Induced Intrahepatic Cholestasis. Dig Dis Sci 47, 2186–2188 (2002). https://doi.org/10.1023/A:1020170807742
Issue Date:
DOI: https://doi.org/10.1023/A:1020170807742